B cell responses to CpG correlate with CXCL16 expression levels in common variable immunodeficiency.

Area of Science:

• Immunology
• Cell Biology
• Molecular Medicine

Background:

• Common variable immunodeficiency (CVID) is characterized by impaired B cell function.
• Toll-like receptor 9 (TLR9) signaling, crucial for B cell activation, is often defective in CVID.
• CXCL16, a cell surface receptor, has recently emerged as a modulator of CpG-induced responses.

Purpose of the Study:

• To investigate the expression and function of CXCL16 on B cells in CVID patients.
• To determine if CXCL16 expression correlates with TLR9-mediated B cell responses in CVID.

Main Methods:

• Flow cytometry was used to analyze CXCL16 expression on B cells from healthy controls and CVID patients.
• In vitro CpG stimulation was performed to assess B cell responses, including upregulation of CD69, CD86, AICDA, and IL-6 production.
• Correlation analysis was conducted between CXCL16 expression levels and functional B cell responses.

Main Results:

• CXCL16 is expressed on B cells across peripheral maturation stages in healthy individuals.
• A subset of CVID patients exhibited decreased CXCL16 expression on their B cells.
• Reduced CXCL16 expression in CVID patients correlated with impaired in vitro responses to CpG stimulation, including defective upregulation of activation markers and cytokine production.

Conclusions:

• B cell CXCL16 expression is normally maintained during peripheral maturation.
• Decreased B cell CXCL16 expression is associated with defective TLR9-mediated responses in a subgroup of CVID patients.
• CXCL16 surface receptor levels may serve as a potential biomarker for B cell responsiveness in common variable immunodeficiency.